Thyroid Lymphoma
Thyroid Lymphoma
复制标题
甲状腺淋巴瘤
DOI：
10.1007/978-4-431-56435-5_4
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Wakai Nobuhide
中科院分区：
文献类型：
--
作者：
Hasegawa Masatoshi;Wakai Nobuhide
原发性甲状腺淋巴瘤相对罕见，约占所有淋巴瘤的1-2%，并且通常与甲状腺疾病如桥本甲状腺炎相关。大多数肿瘤由弥漫性大B细胞淋巴瘤（DLBCL）或粘膜相关淋巴组织结边缘区B细胞淋巴瘤（MALT淋巴瘤）组成。局部侵袭性淋巴瘤（如DLBCL）通常采用免疫/化疗（R-CHOP）治疗，伴或不伴放射治疗。30-40戈伊剂量的受累部位放射治疗（ISRT）被推荐用于联合免疫/化疗（R-CHOP）后的局部侵袭性淋巴瘤。局部惰性淋巴瘤，如MALT和滤泡性淋巴瘤，通常在活检后单独进行放射治疗。对于惰性淋巴瘤，推荐24-30戈伊的ISRT剂量。在某些情况下，还采用其他治疗方式。组织病理学亚型、分期、年龄和治疗（放疗或手术）已被认为是重要的预后因素。由于患者数量有限，需要使用更大队列的疾病特异性方法来确认治疗策略。
Primary thyroid lymphoma is relatively rare, accounting for approximately 1–2% of all lymphomas, and it is often associated with thyroid diseases such as Hashimoto’s thyroiditis. The majority of the tumors consist of diffuse large B-cell lymphoma (DLBCL) or extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Localized aggressive lymphomas such as DLBCL are usually treated with immune/chemotherapy (R-CHOP) with or without radiation therapy. Doses of 30–40 Gy of involved site radiation therapy (ISRT) are recommended for localized aggressive lymphomas following combined immune/chemotherapy (R-CHOP). Localized indolent lymphomas such as MALT and follicular lymphomas are usually treated with radiation therapy alone following biopsy. A dose of 24–30 Gy of ISRT is recommended for indolent lymphomas. Other treatment modalities are performed in some cases. The histopathological subtype, stage, age, and treatment (radiation or surgery) have been suggested to be important prognostic factors. More disease-specific approaches using large cohorts are required to confirm the treatment strategies because the number of patients is limited.